Conference call interim report
Invitation to attend XVIVO Perfusion’s conference call regarding presentation of the interim report for the period April-June, 2014. The presentation will be held in English.
Time: Wednesday, August 13, 2014 at 2.00 p.m. CET
Registration can preferably be done in advance under the following link: https://engage.vevent.com/rt/xvivoperfusion~20140813_webcast
or shortly before time of the conference starts on:
Sweden dial in number: 0200884746
International dial in number: +44 (0) 1452 558567
Conference name: XVIVO Perfusion, conference ID: 67955875
Participants from XVIVO Perfusion:
Magnus Nilsson, CEO
Christoffer Rosenblad, CFO
The press release for XVIVO Perfusion’s interim report for the period January – June, 2014 will be released before the conference call August 13, 2014.
Before the conference call, slides will be available at the company web page, www.xvivoperfusion.com/corporate/.
August 7, 2014
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, christoffer.rosenblad@xvivoperfusion.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
Tags: